These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14224243)

  • 1. FAILURE OF U.S.P. DISINTEGRATION TEST TO ASSESS PHYSIOLOGIC AVAILABILITY OF ENTERIC COATED TABLETS.
    LEVY G; HOLLISTER LE
    N Y State J Med; 1964 Dec; 64():3002-5. PubMed ID: 14224243
    [No Abstract]   [Full Text] [Related]  

  • 2. STUDIES OF DELAYED-ACTION MEDICATION. IV. SALICYLATES.
    HOLLISTER LE; KANTER SL
    Clin Pharmacol Ther; 1965; 6():5-11. PubMed ID: 14253285
    [No Abstract]   [Full Text] [Related]  

  • 3. RELATIONSHIP BETWEEN RATE OF DISSOLUTION, DISINTEGRATION TIME, AND PHYSIOLOGICAL AVAILABILITY OF RIBOFLAVIN IN SUGAR-COATED TABLETS.
    MIDDLETON EJ; DAVIES JM; MORRISON AB
    J Pharm Sci; 1964 Nov; 53():1378-80. PubMed ID: 14253600
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of the formulation of enterosoluble preparations on the physiologic dispensation of the active principle. Part 2: Effect of the elevation of disintegration time of coated tablets by augmentation of dentistry of coating on absorption characteristics of acetylsalicylic acid].
    Delporte JP; Jaminet F
    J Pharm Belg; 1976; 31(1):38-50. PubMed ID: 1255403
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of formulation of enterosoluable preparations on the physiologic availability of the active principle. 1: Effect on the rate of liberation of acetylsalicylic acid from enteric tablets on absorption characteristics in vivo].
    Delporte JP; Jaminet F
    J Pharm Belg; 1975; 30(2):99-113. PubMed ID: 1206458
    [No Abstract]   [Full Text] [Related]  

  • 6. BLOOD ETHIONAMIDE LEVELS AFTER ADMINISTRATION OF ENTERIC-COATED AND UNCOATED TABLETS.
    GROENROOS JA; TOIVANEN A
    Curr Ther Res Clin Exp; 1964 Feb; 6():105-14. PubMed ID: 14135293
    [No Abstract]   [Full Text] [Related]  

  • 7. [Influence of formulation of enteric coated tablets on the bioavailability of the drug. 4th Part: Influence of the enteric polymer dissolution pH on the "in vivo" absorption of aspirin from coated tablets (author's transl)].
    Delporte JP; Jaminet F
    J Pharm Belg; 1976; 31(3):263-76. PubMed ID: 8603
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
    Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is all aspirin alike?
    Med Lett Drugs Ther; 1974 Jul; 16(14):57-9. PubMed ID: 4427568
    [No Abstract]   [Full Text] [Related]  

  • 10. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteric coated naproxen tablets.
    Gamst ON
    Eur J Rheumatol Inflamm; 1992; 12(2):5-8. PubMed ID: 1364940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
    Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA
    Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic inequivalence of pharmaceutical alternates.
    Levy RA
    Am Pharm; 1985 Apr; NS25(4):28-39. PubMed ID: 3893084
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative bioavailability of slow release dicbfenac (Voveran SR) with enteric coated tablet and internationally used Voltaren retard.
    Kumar PD
    J Assoc Physicians India; 1992 Jul; 40(7):483. PubMed ID: 1484038
    [No Abstract]   [Full Text] [Related]  

  • 15. Poor clinical response to enteric-coated iron preparations.
    Rudinskas L; Paton TW; Walker SE; Dotten DA; Cowan DH
    CMAJ; 1989 Sep; 141(6):565-6. PubMed ID: 2776097
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of Calcium Ions on the Disintegration of Enteric-Coated Solid Dosage Forms.
    Al-Gousous J; Langguth P
    J Pharm Sci; 2016 Feb; 105(2):509-511. PubMed ID: 26523769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between physiological availability of salicylates and riboflavin and in vitro disintegration time of enteric coated tablets.
    MORRISON AB; CAMPBELL JA
    J Am Pharm Assoc Am Pharm Assoc; 1960 Jul; 49():473-8. PubMed ID: 13854015
    [No Abstract]   [Full Text] [Related]  

  • 19. Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability.
    Portek I; Graham G; Fleming A
    Med J Aust; 1981 Jul; 2(1):39-40. PubMed ID: 6974303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [RISKS IN THERAPY. GASTRODUODENAL LESIONS CAUSED BY ACETYLSALICYLIC ACID AND THEIR PROPHYLAXIS].
    LENTINI T; STOCCHI F
    Clin Ter; 1964 Apr; 29():3-31. PubMed ID: 14145523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.